To receive CME credit for this program:
- Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
- Review the article and illustration
- Login or register at the CME post test website (http://www.bucmetest.com)
- Locate the course code I.ANG11NSCLC and take the test
Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation
ACCREDITATION STATEMENT
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.
RELEASE AND EXPIRATION
Date of original release: September 30, 2011
Date of expiration: September 29, 2012
Estimated Time To Complete: 1.5 Hours
CME Course Code: I.ANG11NSCLC
TARGET AUDIENCE
Practicing oncologists in the U.S., researchers and medical students
HEALTHCARE GAP
In the United States alone, more than 222,520 new cases of lung cancer were diagnosed in 2010, and an estimated 157,300 people died from this disease. Approximately 85% of lung cancers are a variety called non-small cell lung cancer (NSCLC), which are actually a number of tumor subtypes that originate in lung epithelial cells. The outlook for people with lung cancer that has spread (metastasized) to other organs of the body is almost uniformly grim: most patients with metastatic disease treated with standard chemotherapy survive for less than one year. Because of this poor prognosis, there is an urgent need for better treatments.
A critical need exists to develop strategies that may increase the degree of the anti-tumor effects with the hope of inducing more complete responses impeding the onset of or elimination of refractory disease. Combinations of these and other targeted agents may overcome the resistance that develops with single-agent therapy and could be incorporated either as part of initial therapy or later when disease resistance develops. A new generation of cancer drugs that block tumor blood vessel growth are giving many cancer patients and their loved ones reason for optimism. These drugs, called angiogenesis inhibitors, disrupt the action of angiogenesis-stimulating growth factors, thereby interfering with the supply of blood and nutrients to the cancer. The relatively new approaches to lung cancer management lead to a critical need to rapidly and effectively educate physicians about: pathways and mechanisms; strategies by which new treatments are being integrated into traditional therapeutic protocols; side effects of antiangiogenic therapy for lung cancer and how to integrate it’s management into a treatment strategy; efficacy and safety data emerging from well-designed and rigorous clinical studies; and how this data can directly be used to improve clinical decision-making and outcomes for cancer patients.
PROGRAM LEARNING OBJECTIVES
At the completion of this activity, participants should be able to:
- Describe the role of tumor angiogenesis as both a disease mechanism and the therapeutic targets in NSCLC.
- Explain how antiangiogenic therapies may be integrated into current NSCLC treatment regimens, including front-line and second-line settings.
- Discuss clinical efficacy and safety data from recent studies on antiangiogenic therapies for NSCLC.
- Describe common safety concerns and risk factors of antiangiogenic cancer therapy and their management, including pulmonary embolism.
- Discuss novel antiangiogenic treatments under investigation for NSCLC, including vascular disrupting agents (VDAs).
- Discuss new data on predictive biomarkers for antiangiogenic therapy.
METHOD OF PARTICIPATION
There are no fees for participating in and receiving credit for this online educational activity. The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation. This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section. A print version is also available; for more information contact outreach@angio.org. After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11NSCLC.
ACKNOWLEDGEMENT OF SUPPORT
This activity is supported by educational grants from Genentech.
COURSE FACULTY
Vicki L. Keedy, M.D., MSCI
Assistant Professor of Medicine
Vanderbilt-Ingram Cancer Center
DISCLOSURE
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Vicki L. Keedy, M.D., MSCI, Vanderbilt-Ingram Cancer Center
Faculty
Dr. Keedy has nothing to disclose with regard to commercial interests.
William W. Li, M.D.,
President, the Angiogenesis Foundation, Editor-in-Chief
Dr. Li has nothing to disclose with regard to commercial interests.
Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine
Course Director
Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.
Jody Walker, M.S.
BUSM CME Program Manager
BUSM CME Program Manager has nothing to disclose with regard to commercial interests.
Roderick A. Smith, M.S.
Medical Writer, Program Manager, the Angiogenesis Foundation
Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.
DISCUSSION OF UNLABELLED USE
This CME activity contains discussion of published and/or investigational use of: aflibercept (VEGF Trap), ASA404 (vadimezan), bevacizumab (Avastin®), cetuximab (Erbitux®), erlotinib (Tarceva®), linifanib (ABT 869), motesanib, ramucirumab (IMC-1121B), sorafenib (Nexavar®), tivantinib, and vandetanib (ZD6474).
PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
TOPICS AND EDUCATIONAL CONTENT
Antiangiogenic therapy for advanced and metastatic NSCLC:
- Mechanisms of action and rationale for antiangiogenic agents for lung cancer treatment
- Bevacizumab for NSCLC
- Small molecule angiogenesis inhibitors
- Other investigational treatment strategies
- Side effects
- Conclusions and future directions
SYSTEM REQUIREMENTS
This educational program is available in PDF format. To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.
If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme
For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.
Copyright 2011 by the Angiogenesis Foundation. All rights reserved.
|
